1. Phylogeny  
AKT2, also known as Protein Kinase B beta (PKBβ) or RAC-beta serine/threonine-protein kinase, belongs to the AGC family of serine/threonine kinases. It is one of the three members of the AKT isoenzyme group – the others being AKT1 (PKBα) and AKT3 (PKBγ) – and its evolution can be traced back to the common ancestors of metazoans. AKT2 orthologs are present in all sequenced mammalian species and are widely conserved among eukaryotes. Although AKT isoforms share high overall sequence similarity, subtle differences in their regulatory regions have allowed functional diversification. Phylogenetic analyses indicate that the conserved catalytic core of the AGC kinases, including related kinases such as PDK1, PKC, and SGK, emerged early in evolution and persist today as part of an evolutionary core that modulates growth factor and insulin receptor signaling (brognard2008phlippingtheswitch pages 1-2, kumar2005aktcrystalstructure pages 2-3).

2. Reaction Catalyzed  
AKT2 catalyzes the phosphorylation of specific serine/threonine residues on substrate proteins by transferring the gamma phosphate from ATP. The general chemical reaction that it catalyzes can be represented as:  
  ATP + [protein]-(L-serine or L-threonine) → ADP + [protein]-(L-serine/threonine)-phosphate + H⁺  
This reaction underlies AKT2’s ability to modulate the functional activity of over 100 substrates that participate in diverse cellular processes such as metabolism, cell survival, proliferation, and growth (kumar2005aktcrystalstructure pages 2-3, newton2003regulationofthe pages 1-2).

3. Cofactor Requirements  
The catalytic activity of AKT2, like that of other serine/threonine kinases in the AGC family, depends on divalent metal ions. Specifically, AKT2 requires Mg²⁺ as an essential cofactor, which facilitates the binding of ATP in the active site and is crucial for proper positioning of the phosphate groups during the transfer reaction (kumar2005aktcrystalstructure pages 2-3).

4. Substrate Specificity  
AKT2 exhibits substrate specificity that is largely determined by the recognition of a consensus phosphorylation motif present in its substrates. This motif is commonly represented as Arg–X–Arg–X–X–Ser/Thr–Hydrophobic, where “Hydrophobic” denotes a bulky hydrophobic residue. For example, AKT2 phosphorylates substrates such as the serine 50 residue of PTPN1, which is involved in regulating insulin receptor dephosphorylation, and the phosphorylation of TBC1D4, which is critical for insulin-stimulated glucose transport. In addition, substrates such as GSK3A are phosphorylated by AKT2, thereby influencing glycogen synthesis. Here the conserved nature of the consensus motif ensures that AKT2 selects appropriate substrates in the context of insulin signaling and other growth factor–mediated responses. The specificity has been further detailed by studies mapping the substrate preferences for the human serine/threonine kinome, which include the AKT isoforms (toker2014signalingspecificityin pages 8-10, elangeeb2023insilicoinvestigation pages 1-2).

5. Structure  
AKT2 is organized into three primary domains that contribute to its catalytic and regulatory functions. The N-terminal region contains a pleckstrin homology (PH) domain that mediates binding to phosphoinositides such as phosphatidylinositol 3,4,5-trisphosphate (PIP3); this interaction is responsible for the translocation of AKT2 to the plasma membrane upon stimulation by phosphoinositide 3-kinase (PI3K). The central catalytic domain is highly conserved among AKT isoforms and provides the active site for substrate phosphorylation. Following the catalytic domain, a C-terminal regulatory tail contains a hydrophobic motif. Activation of AKT2 is achieved through a coordinated multi-step process that involves membrane recruitment by the PH domain followed by phosphorylation at key regulatory sites—specifically, at a threonine residue in the activation loop (Thr309 in AKT2) and at a serine residue in the hydrophobic motif (Ser474 in AKT2). Structural studies using crystallography have revealed conformational rearrangements in the kinase domain upon these phosphorylation events that facilitate substrate access to the catalytic cleft. These phosphorylation events promote optimal alignment of the C-helix and stabilization of the hydrophobic spine, which are critical for enzymatic activity. The overall three-dimensional architecture has been modeled based on high-resolution crystal structures and AlphaFold predictions, which together confirm the conserved domain organization and highlight isoform-specific differences in regulatory regions that may underlie functional divergence (kumar2005aktcrystalstructure pages 2-3, restuccia2012proteinkinaseb pages 1-7, kumar2005aktcrystalstructure pages 6-7).

6. Regulation  
AKT2 activity is tightly regulated by multiple mechanisms that ensure its proper spatiotemporal activation in response to extracellular cues. Activation begins with the binding of the PH domain to membrane phosphoinositides (primarily PIP3), which are generated by PI3K in response to growth factor or insulin receptor stimulation. Once localized to the membrane, AKT2 is phosphorylated on its activation loop (Thr309) by phosphoinositide-dependent kinase-1 (PDK1). Full activation requires an additional phosphorylation at the hydrophobic motif (Ser474), which is primarily carried out by the mTOR complex 2 (mTORC2); in some contexts, DNA-dependent protein kinase (DNA-PK) may also contribute. A third phosphorylation site, within the turn motif, is typically constitutive and contributes to the structural stability of the protein. Inactivation of AKT2 is mediated by phosphatases such as PHLPP1, which selectively dephosphorylates the hydrophobic motif, thereby attenuating downstream signaling. Negative regulation is also afforded by PTEN, which dephosphorylates PIP3 to PIP2, thus reducing membrane recruitment of AKT2. Other regulatory inputs include differential phosphorylation by kinases such as CK2, although sequence determinants in AKT2 (for example, a threonine residue acting as a negative determinant) modulate substrate recognition by CK2 compared to AKT1 (vilardell2018theimportanceof pages 15-17). The overall regulation of AKT2 is characterized by a delicate balance between activating phosphorylation events and deactivating phosphatase reactions that determine its activity in processes such as insulin signaling and cell survival (brognard2008phlippingtheswitch pages 1-2, newton2003regulationofthe pages 1-2, hirsch2007phosphoinositide3kinasesas pages 12-12).

7. Function  
AKT2 plays a central role in multiple critical cellular processes. It is especially prominent in mediating insulin signaling and maintaining glucose homeostasis. One of its key functions in metabolic regulation is the promotion of glucose uptake. Through phosphorylation of substrates like TBC1D4, AKT2 triggers the binding of these effectors to inhibitory 14-3-3 proteins, which is required for the insulin-induced translocation of the GLUT4 glucose transporter to the plasma membrane. AKT2 also phosphorylates PTPN1 at serine 50, which serves to inhibit its phosphatase activity and thereby prevents the dephosphorylation of the insulin receptor, ensuring sustained signaling. In addition, AKT2 phosphorylates targets involved in glycogen synthesis such as GSK3A, hence contributing to the storage of glucose in the form of glycogen. Beyond its role in metabolic regulation, AKT2 is implicated in cell growth, proliferation, and survival, with its downstream signaling promoting anti-apoptotic responses and cell cycle progression. AKT2 activity is also linked to oncogenic processes; dysregulation caused by overactivation or loss of negative regulators such as PTEN can contribute to tumorigenesis and cancer progression. In many human cancers, aberrant activation of AKT2 supports cellular survival, migration, and invasion, distinguishing its role from the other AKT isoforms that may have differing influences on tumor behavior. Mouse models have further provided evidence that specific loss of AKT2 contributes to insulin resistance and a diabetes-like phenotype, highlighting its unique function in tissues that are sensitive to insulin, such as muscle and adipose tissue (elangeeb2023insilicoinvestigation pages 1-2, brognard2008phlippingtheswitch pages 5-7, toker2014signalingspecificityin pages 1-3, restuccia2012proteinkinaseb pages 7-10).

8. Other Comments  
Several inhibitors targeting AKT2 have been developed, including both ATP-competitive and allosteric compounds. The design of isoform-selective inhibitors has been a focus in order to modulate AKT2 activity with improved specificity while minimizing off-target effects. In addition, research has identified non-synonymous single nucleotide polymorphisms (nsSNPs) in the AKT2 gene (e.g., p.A179T and p.L183Q) that are predicted to reduce protein stability and function. Such variants have been implicated in the pathogenesis of insulin resistance and type 2 diabetes, underscoring the clinical importance of AKT2 in metabolic disease context (elangeeb2023insilicoinvestigation pages 1-2, elangeeb2023insilicoinvestigation pages 19-23). Furthermore, the deregulation of AKT2 signaling has significant associations with cancer development; its overactivation—often a consequence of upstream mutations in components of the PI3K pathway or loss of PTEN—is linked to enhanced cell proliferation, migration, and resistance to apoptosis (brognard2008phlippingtheswitch pages 7-8, toker2014signalingspecificityin pages 5-7). Given these disease associations, AKT2 continues to be a prominent target in ongoing efforts to develop therapeutic interventions for both cancer and metabolic disorders. In addition, structural studies have provided the framework for the rational design of inhibitors that exploit the unique regulatory and catalytic features of AKT2, such as its distinct domain organization and allosteric control mechanisms (kumar2005aktcrystalstructure pages 3-5, restuccia2012proteinkinaseb pages 10-16).  


References

1. (brognard2008phlippingtheswitch pages 1-2): John Brognard and Alexandra C. Newton. Phlipping the switch on akt and protein kinase c signaling. Trends in Endocrinology &amp; Metabolism, 19:223-230, Aug 2008. URL: https://doi.org/10.1016/j.tem.2008.04.001, doi:10.1016/j.tem.2008.04.001. This article has 233 citations.

2. (brognard2008phlippingtheswitch pages 5-7): John Brognard and Alexandra C. Newton. Phlipping the switch on akt and protein kinase c signaling. Trends in Endocrinology &amp; Metabolism, 19:223-230, Aug 2008. URL: https://doi.org/10.1016/j.tem.2008.04.001, doi:10.1016/j.tem.2008.04.001. This article has 233 citations.

3. (elangeeb2023insilicoinvestigation pages 1-2): M. E. Elangeeb, Imadeldin Elfaki, M. A. Elkhalifa, Khalid M. Adam, A. O. Alameen, Ahmed Kamaleldin Elfadl, Ibrahim Altedlawi Albalawi, Kholoud S. Almasoudi, Reema Almotairi, Basim S. O. Alsaedi, Marwan H. Alhelali, Mohammad Muzaffar Mir, Dnyanesh Amle, and Rashid Mir. In silico investigation of akt2 gene and protein abnormalities reveals potential association with insulin resistance and type 2 diabetes. Current Issues in Molecular Biology, 45:7449-7475, Sep 2023. URL: https://doi.org/10.3390/cimb45090471, doi:10.3390/cimb45090471. This article has 4 citations and is from a peer-reviewed journal.

4. (hirsch2007phosphoinositide3kinasesas pages 12-12): Emilio Hirsch, Carlotta Costa, and Elisa Ciraolo. Phosphoinositide 3-kinases as a common platform for multi-hormone signaling. Journal of Endocrinology, 194:243-256, Aug 2007. URL: https://doi.org/10.1677/joe-07-0097, doi:10.1677/joe-07-0097. This article has 207 citations and is from a peer-reviewed journal.

5. (kumar2005aktcrystalstructure pages 2-3): Chandra C Kumar and Vincent Madison. Akt crystal structure and akt-specific inhibitors. Oncogene, 24:7493-7501, Nov 2005. URL: https://doi.org/10.1038/sj.onc.1209087, doi:10.1038/sj.onc.1209087. This article has 313 citations and is from a domain leading peer-reviewed journal.

6. (kumar2005aktcrystalstructure pages 3-5): Chandra C Kumar and Vincent Madison. Akt crystal structure and akt-specific inhibitors. Oncogene, 24:7493-7501, Nov 2005. URL: https://doi.org/10.1038/sj.onc.1209087, doi:10.1038/sj.onc.1209087. This article has 313 citations and is from a domain leading peer-reviewed journal.

7. (restuccia2012proteinkinaseb pages 1-7): Protein kinase B : the beta version elucidating novel contributions of protein kinase B beta (PKBß/Akt2) to endocrine metabolism, PCOS and cancer

8. (restuccia2012proteinkinaseb pages 10-16): Protein kinase B : the beta version elucidating novel contributions of protein kinase B beta (PKBß/Akt2) to endocrine metabolism, PCOS and cancer

9. (restuccia2012proteinkinaseb pages 7-10): Protein kinase B : the beta version elucidating novel contributions of protein kinase B beta (PKBß/Akt2) to endocrine metabolism, PCOS and cancer

10. (brognard2008phlippingtheswitch pages 7-8): John Brognard and Alexandra C. Newton. Phlipping the switch on akt and protein kinase c signaling. Trends in Endocrinology &amp; Metabolism, 19:223-230, Aug 2008. URL: https://doi.org/10.1016/j.tem.2008.04.001, doi:10.1016/j.tem.2008.04.001. This article has 233 citations.

11. (elangeeb2023insilicoinvestigation pages 19-23): M. E. Elangeeb, Imadeldin Elfaki, M. A. Elkhalifa, Khalid M. Adam, A. O. Alameen, Ahmed Kamaleldin Elfadl, Ibrahim Altedlawi Albalawi, Kholoud S. Almasoudi, Reema Almotairi, Basim S. O. Alsaedi, Marwan H. Alhelali, Mohammad Muzaffar Mir, Dnyanesh Amle, and Rashid Mir. In silico investigation of akt2 gene and protein abnormalities reveals potential association with insulin resistance and type 2 diabetes. Current Issues in Molecular Biology, 45:7449-7475, Sep 2023. URL: https://doi.org/10.3390/cimb45090471, doi:10.3390/cimb45090471. This article has 4 citations and is from a peer-reviewed journal.

12. (kumar2005aktcrystalstructure pages 6-7): Chandra C Kumar and Vincent Madison. Akt crystal structure and akt-specific inhibitors. Oncogene, 24:7493-7501, Nov 2005. URL: https://doi.org/10.1038/sj.onc.1209087, doi:10.1038/sj.onc.1209087. This article has 313 citations and is from a domain leading peer-reviewed journal.

13. (newton2003regulationofthe pages 1-2): Alexandra C. NEWTON. Regulation of the abc kinases by phosphorylation: protein kinase c as a paradigm. Biochemical Journal, 370:361-371, Mar 2003. URL: https://doi.org/10.1042/bj20021626, doi:10.1042/bj20021626. This article has 1070 citations and is from a domain leading peer-reviewed journal.

14. (toker2014signalingspecificityin pages 1-3): Alex Toker and Sandra Marmiroli. Signaling specificity in the akt pathway in biology and disease. Advances in Biological Regulation, 55:28-38, May 2014. URL: https://doi.org/10.1016/j.jbior.2014.04.001, doi:10.1016/j.jbior.2014.04.001. This article has 235 citations and is from a peer-reviewed journal.

15. (toker2014signalingspecificityin pages 5-7): Alex Toker and Sandra Marmiroli. Signaling specificity in the akt pathway in biology and disease. Advances in Biological Regulation, 55:28-38, May 2014. URL: https://doi.org/10.1016/j.jbior.2014.04.001, doi:10.1016/j.jbior.2014.04.001. This article has 235 citations and is from a peer-reviewed journal.

16. (toker2014signalingspecificityin pages 8-10): Alex Toker and Sandra Marmiroli. Signaling specificity in the akt pathway in biology and disease. Advances in Biological Regulation, 55:28-38, May 2014. URL: https://doi.org/10.1016/j.jbior.2014.04.001, doi:10.1016/j.jbior.2014.04.001. This article has 235 citations and is from a peer-reviewed journal.

17. (vilardell2018theimportanceof pages 15-17): Jordi Vilardell, Cristina Girardi, Oriano Marin, Giorgio Cozza, Lorenzo A. Pinna, and Maria Ruzzene. The importance of negative determinants as modulators of ck2 targeting. the lesson of akt2 s131. PLOS ONE, 13:e0193479, Mar 2018. URL: https://doi.org/10.1371/journal.pone.0193479, doi:10.1371/journal.pone.0193479. This article has 2 citations and is from a peer-reviewed journal.